SCHEMBL25353767

SCHEMBL25353767

CC(C)(C)OC(=O)COCc1c(Br)ccc(F)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SSTR4 P31391 1/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33
▸ ALOX5AP P20292 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ MTNR1A P48039 2/20 0.33
▸ MTNR1B P49286 2/20 0.33
▸ PSEN1 P49768 3/20 0.32
▸ PSEN2 P49810 3/20 0.32
▸ APH1B Q8WW43 3/20 0.32
▸ NCSTN Q92542 3/20 0.32
▸ APH1A Q96BI3 3/20 0.32
▸ PSENEN Q9NZ42 3/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25356082 0.80 PKM (0.40) KMT2AL3MBTL1
SCHEMBL25352654 0.75 MEN1 (0.36) MEN1KMT2ARAB9A
SCHEMBL9785547 0.73 CTSS (0.31) MTNR1AMTNR1BMEN1KMT2AGAA
SCHEMBL31484604 0.71 ALDH1A1 (0.42) MTNR1AMTNR1BMEN1KMT2AMAPT
SCHEMBL20136944 0.71 ALOX5AP (0.40) SSTR4ALOX5APFEN1MTNR1AMTNR1B
SCHEMBL15270503 0.71 CACNA1B (0.42) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL361329 0.71 KMT2A (0.43) MEN1KMT2AL3MBTL1
SCHEMBL12145867 0.69 PKM (0.49) MTNR1AMTNR1BPSEN1PSEN2APH1B
SCHEMBL31724729 0.69 SSTR4 (0.33) SSTR4GPR119ALOX5APFEN1MTNR1A
SCHEMBL21113935 0.69 GPR119 (0.44) GPR119PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114374-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2025-04-10 — — US disclosed
WO-2023122000-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. (US) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114374-A1 BCL-2 INHIBITORS BCL2, BCL2L1, BCL2L10 SSTR4 2329/4885GPR119 1537/4885ALOX5AP 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback